<DOC>
	<DOCNO>NCT00406380</DOCNO>
	<brief_summary>Evaluation efficacy Intravitreal Injection Bevacizumab patient Yuxtafoveal Telangiectasias</brief_summary>
	<brief_title>Effect Avastin Juxtafoveal Telangiectasias</brief_title>
	<detailed_description>After diagnose Yuxtafoveal telangiectasias secondary Branch Retinal Vein Occlusion Idiopathic Ethiology clinical sign Fluorescein angiogram ( FA ) finding treat patient Intravitreal Injection Bevacizumab ( 2.5mg/0.1ml ) . We perform complete ophthalmological evaluation baseline follow-up ( 1 3 month ) evaluate ETDRS Best Corrected visual acuity ( BCVA ) , fluorescein angiogram ( FA ) Optical Coherence Tomography ( OCT ) finding . We find improvement visual acuity reduction FA leakage decrease retinal thickness OCT .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients Telangiectasias secondary Branch Retinal Vein Occlusion Patients Idiopathic Juxtafoveal Retinal Telangiectasias Diabetic Retinopathy Diabetic Macular Edema Hypertensive Retinopathy Choroidal Neovascularization</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Telangiectasias</keyword>
	<keyword>Leakage</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Telangiectasias secondary Branch Retinal Vein Occlusion ( BRVO )</keyword>
	<keyword>Idiopathic juxtafoveal retinal telangiectasias</keyword>
</DOC>